Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 5, 2014, Pages 607-619

  Fox, Edward ^a   Edwards, Keith ^b   Burch, Gordon ^c   Wynn, Daniel R ^d   Laganke, Chris ^e   Crayton, Heidi ^f   Hunter, Samuel F ^g   Huffman, Cynthia ^h   Kim, Edward ⁱ   Pestreich, Linda ⁱ   McCague, Kevin ⁱ   Barbato, Luigi ⁱ  

^a Central Texas Neurology Consultants   (United States)

^b Multiple Sclerosis Center of Northeastern   (United States)

^c Blue Ridge Research Center   (United States)

^d Consultants in Neurology Multiple Sclerosis Center ^*  (United States)

^e North Central Neurology   (United States)

^f Multiple Sclerosis Center of Greater Washington   (United States)

^g Advanced Neurosciences Institute   (United States)

^h Meridien Research   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Depression; Fatigue; Fingolimod; Multiple sclerosis; Satisfaction

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BRADYCARDIA; BRONCHITIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CAPSULE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEADACHE; HEART ATRIUM FLUTTER; HEART PALPITATION; HEART VENTRICLE FLUTTER; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NONCARDIAC CHEST PAIN; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; RHINOPHARYNGITIS; RISK REDUCTION; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SELF REPORT; SINUSITIS; TACHYCARDIA; TREATMENT DURATION; TREATMENT SATISFACTION QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CANADA; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; CANADA; DRUG SUBSTITUTION; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; UNITED STATES;

EID: 84906316755     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.06.005     Document Type: Article

References (41)

1. N Agashivala, and E. Kim Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis Clin Ther 34 2012 1583 1590
2. RC Arnau, MW Meagher, MP Norris, and R. Bramson Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients Health Psychol 20 2001 112 119
3. MJ Atkinson, A Sinha, SL Hass, SS Colman, RN Kumar, and M. Brod et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 2004 12
4. A. Bayas Improving adherence to injectable disease-modifying drugs in multiple sclerosis Expert Opin Drug Deliv 10 2013 285 287
5. M Berk, F Ng, S Dodd, T Callaly, S Campbell, and M. Bernardo et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use J Eval Clin Pract 14 2008 979 983
6. DW Brandes, T Callender, E Lathi, and S. O'Leary A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events Curr Med Res Opin 25 2009 77 92
7. V Brinkmann, A Billich, T Baumruker, P Heining, R Schmouder, and G. Francis et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 2010 883 897
8. KA Buzzard, SA Broadley, and H. Butzkueven What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 13 2012 12665 12709
9. PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, and AT. Reder et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 545 556
10. M Cascione, D Wynn, LM Barbato, L Pestreich, L Schofield, and K. McCague Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design J Med Econ 16 2013 859 865
11. J Cohen, F Barkhof, G Comi, HP Hartung, L Kappos, and B. Khatri et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon α-1a: patient-reported indices for multiple sclerosis (PRIMUS)-activities results from a phase III study (TRANSFORMS) Neurology 74 2010 A543
12. Barkhof F Cohen JA, G Comi, H-P Hartung, BO Khatri, and X. Montalban et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
13. LC Doward, SP McKenna, DM Meads, J Twiss, and BJ. Eckert The development of patient-reported outcome indices for multiple sclerosis (PRIMUS) Mult Scler. 15 2009 1092 1102
14. Francis G., Kappos L., O'Connor P., Collins W., Zhang-Auberson L., de Vera A., et al. Lymphocytes and fingolimod - temporal pattern and relationship with infections. 2010; P442: Poster presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 13-16 October 2010, Gothenburg, Sweden
15. M Hofmann, V Brinkmann, and HG. Zerwes FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs Int Immunopharmacol 6 2006 1902 1910
16. ICH. ICH harmonised tripartite guidelines for good clinical practice E6(R1). In: Proceedings of the International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, Geneva http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf [accessed 27.02.14] 1996.
17. ICH. In: Proceedings of the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) http://www.ich.org/products/guidelines.html [27.02.14] 2013.
18. V Janardhan, and R. Bakshi Quality of life in patients with multiple sclerosis: the impact of fatigue and depression J Neurol Sci 205 2002 51 58
19. C Jenkinson, S Stewart-Brown, S Petersen, and C. Paice Assessment of the SF-36 version 2 in the United Kingdom J Epidemiol Community Health 53 1999 46 50
20. LH Jensen, K Osterlind, and C. Rytter Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC Lung Cancer 62 2008 85 91
21. L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, and P. Calabresi et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
22. JF. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
23. L La Mantia, LM Munari, and R. Lovati Glatiramer acetate for multiple sclerosis Cochrane Database Syst Rev 2010 CD004678
24. AP Lima, and A. del Giglio Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience Eur J Cancer Care 14 2005 151 154
25. S Nikfar, R Rahimi, and M. Abdollahi A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type Clin Ther 32 2010 1871 1888
26. BJ Oliver, E Kohli, and LH. Kasper Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials J Neurol Sci 302 2011 96 105
27. RH Osborne, R De Abreu Lourenco, A Dalton, J Houltram, D Dowton, and DE. Joshua et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study Value Health J Int Soc Pharmacoecon Outcomes Res. 10 2007 451 456
28. L Peidro-Garces, R Otero-Fernandez, and L. Lozano-Lizarraga [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study] Rev Esp Cir Ortop Traumatol 57 2013 53 60
29. CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, and L. Kappos et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
30. N Qizilbash, I Mendez, and R. Sanchez-de la Rosa Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis Clin Ther 34 2012 159 176, e5
31. GP Rice, B Incorvaia, L Munari, G Ebers, C Polman, and R. D'Amico et al. Interferon in relapsing-remitting multiple sclerosis Cochrane Database Syst Rev 2001 CD002002
32. M Sospedra, and R. Martin Immunology of multiple sclerosis Annu Rev Immunol 23 2005 683 747
33. H Tan, Q Cai, S Agarwal, JJ Stephenson, and S. Kamat Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis Adv Ther 28 2011 51 61
34. K Treadaway, G Cutter, A Salter, S Lynch, J Simsarian, and J. Corboy et al. Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 2009 568 576
35. K Treadaway, G Cutter, A Salter, S Lynch, J Simsarian, and J. Corboy et al. Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 2009 568 576
36. C Twelves, S Gollins, R Grieve, and L. Samuel A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer Ann Oncol Off J Eur Soc Med Oncol / ESMO 17 2006 239 245
37. US prescribing information. Gilenya prescribing information. https://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdff [accessed 03.14]2014.
38. PO Valko, CL Bassetti, KE Bloch, U Held, and CR. Baumann Validation of the fatigue severity scale in a Swiss cohort Sleep 31 2008 1601 1607
39. BG Weinshenker, B Bass, GP Rice, J Noseworthy, W Carriere, and J. Baskerville et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course Brain 112 Pt 6 1989 1419 1428
40. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. www.wma.net/en/30publications/ 10policies/b3/index.html [27.02.14] 2014
41. T Ziemssen, P Vollmar, M Meergans, F Tracik, M Diaz Lorente, and K. Neidhardt et al. Interim results of the PANGAEA and PEARL studies, comparing treatment satisfaction and pharmaco-economic data of fingolimod (Gilenya®) and first-line therapies in multiple sclerosis patients in Germany Neurology 80 P03 2013 220